Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Renal ultrasound

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    286 result(s) found for: Renal ultrasound. Displaying page 10 of 15.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    EudraCT Number: 2016-002164-13 Sponsor Protocol Number: UZBRU_VHH1_3 Start Date*: 2017-01-05
    Sponsor Name:UZ Brussel
    Full Title: Quantification of 68GaNOTA-Anti-HER2 VHH1 Uptake in metastasis of Breast carcinoma and cancer patients and Assessment of Repeatability – Pilot study
    Medical condition: Breast cancer; salivary gland cancer; adenocarcinoma of the gastric body or gastro-esophageal junction; endometrial cancer; cancer of cervix uteri; Non-small cell lung cancer; biliary tract cancer;...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001800-13 Sponsor Protocol Number: UC-0101/1306 Start Date*: 2014-09-05
    Sponsor Name:UNICANCER
    Full Title: Neoadjuvant phase II trial combining [3 FEC 100 followed by 3 docetaxel associated with trastuzumab plus pertuzumab] or [6 docetaxel, carboplatin associated with trastuzumab plus pertuzumab] accord...
    Medical condition: Untreated, operable, non-metastatic and HER2-positive breast cancer (BC)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021600-24 Sponsor Protocol Number: FEC Start Date*: 2010-10-16
    Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
    Full Title: FEC neo-adjuvant chemotherapy followed by weekly Taxol administration combined with Trastuzumab in II-III stage HER2 positive breast cancer patients.Fase II trial.
    Medical condition: II/III stage HER2+ eligible for neoadjuvant chemotherapy breast cancer women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007308 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002254-31 Sponsor Protocol Number: THR-PS-03 Start Date*: 2011-11-29
    Sponsor Name:Rigshospitalet, ITA 4131, Department of Intensive care
    Full Title: Double-blinded, randomized trial in severe pneumonia patients with severe sepsis investigating the safety and efficacy of co-administration of iloprost and ascending doses of eptifibatide compared...
    Medical condition: Severe pneumonia with Sepsis and Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001069-28 Sponsor Protocol Number: D5881C00004 Start Date*: 2015-02-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
    Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000568-28 Sponsor Protocol Number: GO28888 Start Date*: 2014-10-16
    Sponsor Name:Genentech, Inc.
    Full Title: A phase II randomized, double-blind study of neoadjuvant letrozole plus GDC-0032 versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer
    Medical condition: WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) CZ (Completed) PT (Completed) HU (Completed) IT (Completed) GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004018-33 Sponsor Protocol Number: PH-F16IL2TAXO-03/12 Start Date*: 2013-05-22
    Sponsor Name:Philogen S.p.A.
    Full Title: A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma.
    Medical condition: Merkel cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005092-13 Sponsor Protocol Number: MO42623 Start Date*: Information not available in EudraCT
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL PHASE IV STUDY TO EVALUATE OVERALL HEALTH, PHYSICAL ACTIVITY, AND JOINT OUTCOMES, IN PARTICIPANTS AGED ≥ 13 AND < 70 YEARS WITH SEVERE OR MODERATE HEMOPHILIA A WITHOUT FVI...
    Medical condition: Severe or Moderate Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004832-48 Sponsor Protocol Number: GN19CA407 Start Date*: 2020-12-17
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: DAPA-RESIST - Sodium glucose cotransporter-2 inhibitor DAPAgliflozin versus thiazide diuretic in patients with heart failure and diuretic RESISTance: a multi-centre, open-label, randomised controll...
    Medical condition: Diuretic resistant heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    20.0 100000004849 10066159 Decompensated heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    20.0 10042613 - Surgical and medical procedures 10053073 Diuretic therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-005876-21 Sponsor Protocol Number: DANOHCA-001 Start Date*: 2022-07-08
    Sponsor Name:Department of Cardiology, Copenhagen University Hospital, Rigshospitalet
    Full Title: The Danish Out-of-Hospital Cardiac Arrest study (DANOHCA)
    Medical condition: We will investigate the efficacy of four interventions (two pharmaceutical) for reducing mortality and organ damage in patients resuscitated after out-of-hospital cardiac arrest.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003109 Arrest cardiac LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005455-37 Sponsor Protocol Number: 178-CL-207 Start Date*: 2022-11-14
    Sponsor Name:Astellas Pharma Global Development Inc.
    Full Title: A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron P...
    Medical condition: Neurogenic detrusor overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10012547 Detrusor hyperreflexia LLT
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003008-42 Sponsor Protocol Number: ZN-d5-003 Start Date*: 2021-12-22
    Sponsor Name:K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
    Full Title: A Single-Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
    Medical condition: Relapsed or Refractory Light-Chain Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004870 10083938 Amyloid light-chain amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed) CY (Completed)
    Trial results: View results
    EudraCT Number: 2011-000553-23 Sponsor Protocol Number: GBG66 Start Date*: 2011-09-29
    Sponsor Name:German Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP)
    Full Title: A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer
    Medical condition: patients with triple-negative breast cancer, patients with HER2-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10021976 Inflammatory breast cancer stage IV LLT
    14.1 100000004864 10063104 Tubular breast cancer stage II LLT
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    14.1 100000004864 10022882 Invasive ductal breast cancer LLT
    14.1 100000004864 10028061 Mucinous breast cancer stage II LLT
    14.1 100000004864 10006188 Breast cancer female NOS LLT
    14.1 100000004864 10063105 Tubular breast cancer stage III LLT
    14.1 100000004864 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005214-11 Sponsor Protocol Number: GBG-68 Start Date*: 2012-08-10
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Neo- / adjuvant phase III trial to compare intense dose-dense chemotherapy to tailored dose-dense chemotherapy in patients with high-risk early breast cancer (GAIN-2 trial)
    Medical condition: Patients with primary breast cancer (now in neoadjuvant or adjuvant setting).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004946-41 Sponsor Protocol Number: SP-PP18 Start Date*: 2019-09-12
    Sponsor Name:Dr. Virgilio P. Carnielli,
    Full Title: Personalized versus standard parenteral nutrition for preterm infants with a birth weight greater than 1250 grams: a phase IV randomized clinical trial
    Medical condition: Growth of preterm infants with a birth weight greater than 1250g on parenteral nutrition.
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003874-29 Sponsor Protocol Number: E-3810-II-02 Start Date*: 2014-01-20
    Sponsor Name:EOS S.p.A.
    Full Title: A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer
    Medical condition: FGFR1-amplified squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004019-11 Sponsor Protocol Number: Troika Start Date*: 2018-07-03
    Sponsor Name:Prestige BioPharma Pte Ltd
    Full Title: A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast...
    Medical condition: Non-metastatic, unilateral, newly diagnosed, operable early breast cancer (EBC) of clinical stage II and III including inflammatory breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) EE (Completed) HU (Completed) BG (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002644-87 Sponsor Protocol Number: B1481021 Start Date*: 2013-11-27
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED,PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLE...
    Medical condition: Heterozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) NL (Completed) NO (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005127-29 Sponsor Protocol Number: TAX_GMA_302 Start Date*: 2001-05-21
    Sponsor Name:SANOFI-AVENTIS
    Full Title: MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC->T) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (HERCEPTI...
    Medical condition: node positive and high risk node negative patients with operable breast cancer containing the the HER2 alteration.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005992-10 Sponsor Protocol Number: 156-201-00307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 18 years of Age with Autosomal Recessive Polycystic Kidne...
    Medical condition: Autosomal Recessive Polycystic Kidney Disease (ARPKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036047 Polycystic kidney, autosomal recessive LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 15:16:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA